RecruitingPhase 3NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Birmingham, AL · +454 more sites
Leukemia clinical trials in Birmingham, AL
19 recruiting leukemia studies with a site in Birmingham, AL.
RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Birmingham, AL · +114 more sites
RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Birmingham, AL · +174 more sites
RecruitingPhase 2NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Birmingham, AL · +224 more sites
RecruitingPhase 1 / Phase 2NCT06137118
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Sponsor: AstraZeneca
Birmingham, AL · +11 more sites
RecruitingPhase 2NCT06315309
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Sponsor: University of Alabama at Birmingham
Birmingham, AL
RecruitingPhase not listedNCT07143669
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Sponsor: Blueprint Medicines Corporation
Birmingham, AL · +23 more sites
RecruitingPhase 3NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Sponsor: Janssen Research & Development, LLC
Birmingham, AL · +58 more sites
RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Birmingham, AL · Mobile, AL · +184 more sites
RecruitingPhase 2NCT06824168
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Sponsor: Daiichi Sankyo
Birmingham, AL · +14 more sites
RecruitingPhase 2NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Sponsor: Cogent Biosciences, Inc.
Birmingham, AL · +13 more sites
RecruitingPhase 1 / Phase 2NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Sponsor: PedAL BCU, LLC
Birmingham, AL · Mobile, AL · +162 more sites
RecruitingPhase not listedNCT05702645
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Sponsor: Children's Oncology Group
Birmingham, AL · +71 more sites
RecruitingPhase 1NCT06247787
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Sponsor: Children's Oncology Group
Birmingham, AL · +18 more sites
RecruitingNot applicableNCT06697600
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Sponsor: University of Rochester
Birmingham, AL · +3 more sites
RecruitingPhase not listedNCT01790152
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Sponsor: Children's Oncology Group
Birmingham, AL · +68 more sites
RecruitingPhase 1NCT07044544
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Sponsor: University of Alabama at Birmingham
Birmingham, AL
RecruitingPhase not listedNCT05556928
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Sponsor: University of Alabama at Birmingham
Birmingham, AL
RecruitingPhase not listedNCT07145411
HPC Offered for PRESERVE Expansion
Sponsor: Ossium Health, Inc.
Birmingham, AL · +3 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.